Skip to content
Menu

United Therapeutics Corporation UTHR

Full chart Compare
Set alert

Price alert · UTHR

All alert types
554.73 USD -4.37 (-0.78%)

Regular-session close

554.73 0.00 0.00%

After hours · Nov 20, 6:11 PM ET

551.77 Day range 563.11
464.93 52-week range 608.49
YTD
+13.85%
1 year
+16.85%

5D -35.76 (-6.06%)

560580MonTueWedThuFri554.73
Market cap
23.63B
Revenue (ttm)
3.19B
Profit margin
38.61%
EPS (ttm)
26.49
Shares out
42.59M
P/E ratio
20.94
Forward P/E
16.48
YTD return
+13.85%
1-year return
+16.85%
50-day average
548.85
Volume
531.78K
Avg volume
703.53K
Open
561.20
Previous close
559.10
Day's range
551.77 – 563.11
52-week range
464.93 – 608.49
Beta
0.48
Analysts
Buy
Price target
687.14 (+23.9%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
539.47
Enterprise value
21.74B
PEG ratio
2.22
Price / sales
7.41
Price / book
3.75
Revenue growth
4.10%
Free cash flow
454.62M
Total cash
2.07B
Return on equity
19.13%
Short % of float
5.04%

Fundamental scorecard

15 of 25 checks passed on UTHR’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 1 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
UTHR Revenue — quarterly 832.50M
UTHR Net income — quarterly 258.60M
UTHR EPS — quarterly 6.06

Earnings

UTHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20264.95———
Nov 4, 2026Sep 30, 20266.015.71-0.30-4.99%
Aug 5, 2026Jun 30, 20266.867.27+0.41+5.98%
May 6, 2026Mar 31, 20267.005.82-1.18-16.86%
Feb 25, 2026Dec 31, 20257.137.70+0.57+7.99%
Oct 29, 2025Sep 30, 20256.897.16+0.27+3.92%

Upgrades / downgrades

UTHR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026TD CowenmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026Wells FargomainOverweightOverweight
Nov 4, 2026BTIGmainBuyBuy
Oct 28, 2026JP MorganmainOverweightOverweight
Oct 22, 2026RBC CapitalmainOutperformOutperform

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
unither.com

News

Your note

Sign in to keep a note on UTHR — it syncs with the Stock Master app.

Insider holders

UTHR insider holders
InsiderRelationLatest transactionDateShares held
BENKOWITZ MICHAELPresidentConversion of Exercise of derivative securityMar 12, 20260
CAUSEY CHRISTOPHERDirectorSaleMar 29, 20264,190
EDGEMOND JAMES C.Chief Financial OfficerConversion of Exercise of derivative securityJun 21, 202618,876
GILTNER RICHARD ADirectorConversion of Exercise of derivative securityJul 8, 202621,884
KURZWEIL RAYMOND CDirectorConversion of Exercise of derivative securityJul 8, 202613,320
MAHON PAUL AGeneral CounselSaleNov 18, 202645,172

Institution ownership

UTHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.09%5,575,1623.09BSep 29, 2026
Avoro Capital Advisors LLC6.47%2,755,5551.53BSep 29, 2026
State Street Corporation4.58%1,952,5571.08BSep 29, 2026
Vanguard Capital Management LLC4.53%1,928,9281.07BSep 29, 2026
Vanguard Portfolio Management LLC4.49%1,911,5301.06BSep 29, 2026
Wellington Management Group, LLP4.46%1,899,6051.05BSep 29, 2026

Fund ownership

UTHR fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.59%1,527,799847.52MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%1,347,720747.62MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%973,490540.02MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.69%719,385399.06MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%486,555269.91MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.76%323,432179.42MSep 29, 2026